Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
about
Opioid antagonists for smoking cessationMedications for unhealthy alcohol use: across the spectrum.Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Opioid modulators for alcohol dependence.Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.Marijuana use and tobacco smoking cessation among heavy alcohol drinkers.Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokersLow-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trialSmokers' Treatment Expectancies Predict Smoking Cessation Success.2013 Update in addiction medicine for the generalist.Predictors of Interest in an Alcohol Reduction Clinical Trial of Naltrexone among UndergraduatesCurrent progress in pharmacologic treatment strategies for alcohol dependence.Using conditioned place preference to identify relapse prevention medications.Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.
P2860
Q24202118-0C1AE6B1-6120-488C-8B64-85E2FC2E059BQ27690692-A9688443-4DBC-4CB4-8A02-3ADFF9F73D02Q34012381-807A6D52-ABB2-4906-A350-6FFC25FF111DQ34167551-AC09CCBF-132B-4E84-97D2-06D52D3C8421Q34190543-2E9D3757-958B-4957-963F-28629B9F4D2DQ34306652-5F6B0670-50CC-46B1-A47E-7670A9B15059Q35195302-08B44AF5-9D14-48A6-B5E8-16F752AAEE9CQ35417708-F9E1CD10-BA3B-4899-933B-C958260F961DQ35689017-17347D46-DFE4-4CB4-9C0B-F8AAEE2731F4Q36133717-1C549AF5-68DA-425F-8FC6-2D114F865B1BQ36223647-83691A1D-1962-4C74-9057-CF38C9C6C02BQ36263819-E873AD24-4916-4B5E-9377-C98EF96583F2Q36774139-DCD5DDFB-B725-4F95-8D4A-B844FDF3B0C0Q36877440-5B1598D2-ABB8-4162-9CF3-90777F411BEAQ37167372-B42AB6BD-19BB-4B58-B0E4-2F367483CD1DQ37179217-D824747B-1A57-4A98-B960-D2C4C1A06B67Q37221715-F4FAEFC9-5BE2-4663-B3E7-E69FA2268F7BQ37284626-F7F07CF0-115B-4860-819B-BDF5446E4355Q37568348-423E0754-19E0-4A03-999B-46F7FE7F8509Q38040129-088A6F67-756D-4A73-9267-F4F0D5F7D0C3Q38107338-A1B1A352-51D6-4A74-A28B-BA74B80A05E7Q38837127-436ACAF1-F73E-4782-A8D4-630806D239B2Q47915520-F852D2FE-4E3B-4B19-9ECB-66E394E21F29Q50042559-E4BAFC9F-B21F-4841-BA05-4A47E1325D18Q50065382-76FF68E8-BCA3-4134-93D7-53026D03F4B5
P2860
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@ast
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@en
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@nl
type
label
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@ast
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@en
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@nl
prefLabel
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@ast
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@en
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@nl
P2093
P2860
P921
P1476
Dose-dependent reduction of ha ...... trexone for smoking cessation.
@en
P2093
Boris Meandzija
Robert F Leeman
Robert W Makuch
Sherry A McKee
Stephanie S O'Malley
P2860
P304
P356
10.1017/S146114570800936X
P577
2008-09-17T00:00:00Z